Cdc2 as prognostic marker in stage UICC II colon carcinomas

European Journal of Cancer

Volumn 45, Issue 8, 2009, Pages 1466-1473

  Meyer, Alexander ^a   Merkel, Susanne ^a   Brückl, Wolfgang ^a   Schellerer, Vera ^a   Schildberg, Claus ^a   Campean, Valentina ^a   Hohenberger, Werner ^a   Croner, Roland S ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cell cycle; Colon cancer; Immunohistochemistry; Prognosis; Tissue array

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 2; FLUOROURACIL; FOLINIC ACID; KI 67 ANTIGEN; PARAFFIN; PROTEIN P53;

ADJUVANT THERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CENTER; CANCER SURVIVAL; CELL PROLIFERATION; COLON CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PUNCH BIOPSY; SCORING SYSTEM; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASPASE 3; COLONIC NEOPLASMS; CYCLIN B; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 65249091438     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.010     Document Type: Article

References (27)

1. Baisse B., Bouzourene H., Saraga E.P., et al. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 93 (2001) 346-352
2. Campling B.G., and El-Deiry W.S. Clinical implication of p53 mutation in lung cancer. Mol Biotechnol 24 (2003) 141-156
3. Campling B.G., and El-Deiry W.S. Clinical implications of p53 mutations in lung cancer. Method Mol Med 75 (2003) 53-77
4. Chang F., Syrjanen S., and Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13 (1995) 1009-1022
5. Cohen T., Prus D., Shia J., et al. Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis. J Surg Oncol 97 (2008) 416-422
6. DiPaola R.S. To arrest or not to G(2)-M cell-cycle arrest: commentary re: A.K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin Cancer Res, 2002;8:3512-9. Clin Cancer Res 8 (2002) 3311-3314
7. Garrett M.D., and Fattaey A. CDK inhibition and cancer therapy. Curr Opin Genet Dev 9 (1999) 104-111
8. Golsteyn R.M. Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle. Cancer Lett 217 (2005) 129-138
9. Grignon D.J., Caplan R., Sarkar F.H., et al. P53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 89 (1997) 158-165
10. Hermanek P. The new TNM classification and staging of stomach cancer. Leber Magen Darm 19 (1989) 169-172 175-9
11. Hermanek P. Surgical pathology - the TNM system. Langenbecks Arch Chir 358 (1982) 57-63
12. Hermanek P., Sobin L.H., Wittekind C., et al. How to improve the present TNM staging system. Cancer 86 (1999) 2189-2191
13. Kuribayashi K., Mayes P.A., and El-Deiry W.S. What are caspases 3 and 7 doing upstream of the mitochondria?. Cancer Biol Ther 5 (2006) 763-765
14. Liu M.C., and Gelmann E.P. P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 29 (2002) 246-257
15. Losi L., Baisse B., Bouzourene H., et al. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26 (2005) 916-922
16. Mazumder S., Plesca D., and Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Method Mol Biol 414 (2008) 13-21
17. Merkel S., Wein A., Gunther K., et al. High-risk groups of patients with stage II colon carcinoma. Cancer 92 (2001) 1435-1443
18. Nurse P. The wellcome lecture, 1992. Cell cycle control. Philos Trans Royal Soc Lond B: Biol Sci 341 (1993) 449-454
19. Ozen M., and Ittmann M. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res 11 (2005) 4701-4706
20. Schmiegel W., Pox C., Adler G., et al. S3-guidelines conference "colorectal carcinoma" 2004. Z Gastroenterol 42 (2004) 1129-1177
21. Schmiegel W., Pox C., Adler G., et al. S3-guideline conference "colorectal cancer" 2004. Dtsch Med Wochenschr 130 Suppl. 1 (2005) S5-53
22. Schmiegel W., Reinacher-Schick A., Arnold D., et al. Update S3-guideline "colorectal cancer" 2008. Z Gastroenterol 46 (2008) 799-840
23. Schmitt E., Boutros R., Froment C., et al. CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage. J Cell Sci 119 (2006) 4269-4275
24. Shimizu T., O'Connor P.M., Kohn K.W., et al. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 55 (1995) 228-231
25. Tyson J.J. Modeling the cell division cycle: cdc2 and cyclin interactions. Proc Natl Acad Sci USA 88 (1991) 7328-7332
26. Weinstein I.B., Begemann M., Zhou P., et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 3 (1997) 2696-2702
27. Yan X., Chua M.S., He J., et al. Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo. Mol Cancer 7 (2008) 19